A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
Latest Information Update: 31 Jan 2024
At a glance
- Drugs Etrasimod (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms GLADIATOR; GLADIATOR UC
- Sponsors Arena Pharmaceuticals; Pfizer
- 23 Jan 2024 Planned End Date changed from 24 Jul 2024 to 18 Jul 2024.
- 23 Jan 2024 Planned primary completion date changed from 24 Jul 2024 to 18 Jul 2024.
- 06 Sep 2023 Planned End Date changed from 17 Jul 2024 to 24 Jul 2024.